about
Denosumab for prevention of fractures in postmenopausal women with osteoporosisDenosumab in postmenopausal women with low bone mineral densityA novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year dataBlood pressure and calcium intake are related to bone density in adult males.Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines.Clinical risk factors and evaluation of the risk of osteoporosis in clinical practice.Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis.Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.Results of special studies with alendronate.The menopause and HRT. Prevention and management of osteoporosis.Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures.Practice guidelines on the use of bone mineral density measurements: Who to test? What measures to use? When to treat? A consensus report from the Middle East Densitometry Workshop.Pathogenesis of osteoporotic hip fractures.Parathyroid hormone for the treatment of osteoporosis.Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.Use of highly potent bisphosphonates in the treatment of osteoporosis.The relationship between bone mineral density and fracture risk.Do current management strategies and guidelines adequately address fracture risk?Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies.Serum protein concentrations and bone mineral content in aging normal men.Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions.Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trialEffects of risedronate on fracture risk in postmenopausal women with osteopeniaA multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group.Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.Discrepancies in normative data between Lunar and Hologic DXA systems.American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond.Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.Osteoporosis update from the 2010 santa fe bone symposium.
P50
Q28254528-0C9DCDDD-8998-4A4C-8073-33E53198DA08Q28298728-F6CDF02B-6A46-4335-A608-FA5B8EA56C6FQ30577427-974B7E1D-3A16-4443-ACBA-61576DB1E6AEQ30829779-723D76D1-E832-409B-918E-33F54F9C84A4Q31921266-761B81D2-A7EB-42B9-895C-7608FEDFD762Q32131242-FDD8FFA9-1B6D-4877-807B-77519B4FE01AQ33707143-322070BA-5A98-4FF2-BC2E-6958DC074CE9Q34061229-14632BAE-6212-4E38-9473-F7F8AE59F19AQ34263882-185940D6-47F9-48EF-BC99-27B12D6296C1Q34548650-9536D588-8ACA-44E2-8DFF-B2AA119A67FBQ34659539-A23B3246-8208-4CAE-8112-4245C97DC2F8Q34842213-E7673782-7F26-4D99-ADEA-78450E4EDAF8Q35096485-BE17E318-1B10-4FDB-913D-F4E7483E748DQ35134594-BB625D10-D3F1-44AA-A427-74B1EC4B3C07Q35198400-634C63B7-3188-4983-8B81-AD8981FD1FBEQ35593707-4918EF3F-8BF8-4EA8-99A5-48B72259FA3FQ35702005-58E8384D-3563-4744-BFF6-30E929A97A88Q35968279-13E03B67-5B5C-4C1D-B34A-5FD672FD162EQ36071882-F63E17FC-54FF-44F9-8A57-DD623BC976B1Q36153174-2ABA7FE5-E1D1-470B-86C3-B14593E575DEQ36164799-C31F180B-DB0A-4EFD-B4C0-F693067ACA1DQ36203243-231F728E-4198-4A4A-8EB6-FCED3B40E6B7Q36203383-3D7D6FC6-018F-4A85-A70D-5906BCB1F4C3Q36364887-22CCEBA5-ED3C-49DA-A513-B7A5B24ED7E0Q36417317-E7B393E4-192E-4CA3-AEAE-FC35D64644AEQ36471817-7AD3A358-FC9D-4365-904E-9369D8A23DDDQ36491297-D67E15AE-DF36-46E8-9E0E-D24B171C91DAQ36508374-9FC174BA-68C9-4C72-A455-D0272FDA8DF5Q36508404-608B54FB-304B-402B-8994-5A8A34160E9FQ36514462-59957778-625C-4254-B96E-C025A538516DQ36816379-2FFD4818-F583-41D5-8B8B-E79CE36318CCQ36832985-1FF9761D-9C96-41E6-8E0A-8BB4545AF760Q36855859-D25F226E-E058-42A1-8FAD-7B1B95474572Q36959809-2DC902CE-8157-4922-AE3C-1E109E60E600Q37058788-D4BEFC80-D02A-49AE-9A21-EEEECEC85A50Q37069667-CCFDF74D-7093-4183-A8A4-8C2F259E7F23Q37415368-E76B8A2A-BCE6-4B62-A2BD-7BB14542DB49Q37620991-63B73A1E-C6BC-4CDB-93FB-FA082C2CF067Q37823835-FA75CF5D-E8C3-41CF-9721-0E45FB4E541FQ37836020-41D32D75-B4DD-44DB-81F4-7A167CE909F7
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Michael R McClung
@ast
Michael R McClung
@en
Michael R McClung
@es
Michael R McClung
@sl
type
label
Michael R McClung
@ast
Michael R McClung
@en
Michael R McClung
@es
Michael R McClung
@sl
altLabel
Michael R McClung
@en
prefLabel
Michael R McClung
@ast
Michael R McClung
@en
Michael R McClung
@es
Michael R McClung
@sl
P214
P244
P106
P21
P213
0000 0000 3777 0886
P214
P244
nb98073371
P31
P496
0000-0002-7827-0778
P734
P735
P7859
lccn-nb98073371